The content on this site is intended for healthcare professionals only
Prof Heinrich Lokhorst talks to ecancer at EHA 18 about results from a phase I/II study in advanced Multiple Myeloma.
Multiple myeloma is the second most common haematological cancer. It is a cancer of the plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment modalities to improve the survival.
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
ecancer's filming at EHA has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
